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Highlights 30 
 The effects of beetroot juice supplementation on BP variability have not been 31 
investigated.  32 
 Beetroot juice decreased nocturnal systolic BP variability in subjects aged less than 33 
65y. 34 
 Greater changes in nitrite concentrations decreased nocturnal mean and variability of 35 
systolic BP.  36 
 37 
 38 
Abstract  39 
Objectives: Abnormal circadian oscillations of blood pressure (BP) and nocturnal-diurnal BP 40 
differences (i.e., dipping) increase cardiovascular risk. Whether inorganic nitrate 41 
supplementation influences 24-hr BP variability is currently unknown. We studied the effects 42 
of high-nitrate beetroot juice supplementation on BP variability measured by 24-hr 43 
ambulatory BP monitoring (24-hr ABPM) in older subjects.   44 
Methods: Data from four independent randomised clinical trials were collated. Eighty-five 45 
older participants (age range: 55-76 years) were included in the final database. Two trials had 46 
an open-label, parallel design and two trials had a cross-over, double-blind design. 47 
Participants were randomised to either beetroot juice or placebo. Changes in 24-hr ABPM 48 
(daily, diurnal, nocturnal), variability (weighted-SDs), night-dipping, morning surge for 49 
systolic and diastolic BP were measured. Meta-analysis was conducted to obtain pooled 50 
estimates of the effect size for each BP outcome. Sub-group analyses were conducted to 51 
evaluate the influence of age, BMI, gender, BP status and changes in nitrite concentrations on 52 
the effect size.  53 
Results The pooled effect of beetroot juice on all BP outcomes was not significant. Beetroot 54 
juice ingestion determined a significant decrease in nocturnal systolic BP variability in 55 
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subjects aged less than 65y (2.8mmHg, -4.5 -1.0, p=0.002) compared to the older group 56 
(≥65y; 1.0mmHg, -2.2 4.2, p=0.54). A greater change in NO2
- 
concentrations after beetroot 57 
supplementation was associated with significant differences for nocturnal mean (-3.4mmHg, -58 
0.6 -2.4, p=0.02) and variability (-0.8mmHg, -1.5 -0.06, p=0.03) of systolic BP. 59 
Conclusions: The vascular responsiveness to inorganic nitrate may be modified by 60 
mechanisms of vascular ageing influencing the reducing capacity to convert inorganic nitrate 61 
into nitrite and tissue-specific responses to dietary nitrate supplementation.  62 
Keywords: ageing, ambulatory blood pressure, beetroot juice, inorganic nitrate, hypertension 63 
 64 
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1. Introduction 65 
Raised blood pressure (BP) is a leading cause of cardiovascular diseases and main contributor 66 
to the global burden of non-communicable diseases[1]. The haemodynamic effects of raised 67 
BP are responsible for the remodelling of cardiac ventricles[2] and intima-media 68 
thickening[3], which increase the risk of cardiovascular diseases such as heart failure or 69 
stroke[4]. There is a continuum of cardiovascular risk that increases as BP rises, and the 70 
theoretical minimum threshold of risk associated with systolic BP has been estimated to be 71 
approximately 115mmHg[5]. For each 2 mmHg rise in systolic BP there is a 7% increased 72 
risk of mortality from ischaemic heart disease and a 10% increased risk of mortality from 73 
stroke[6]. These statistics emphasise the importance of small reductions in BP for the 74 
effective management and prevention of hypertension-related comorbidities. 75 
 76 
Effective nutritional and lifestyle interventions are key to prevent hypertension and related 77 
cardiovascular complications[7]. The reduction of salt intake is an example of a nutritional 78 
intervention with immediate benefits on BP regulation[8]. More recently, inorganic nitrate 79 
(NO3
-
) supplementation has been advanced as a potential, effective nutritional strategy to 80 
control BP[9; 10]. A recent meta-analysis showed a decrease in resting systolic BP of 81 
4.4mmHg after either inorganic NO3
- 
or beetroot juice supplementation[11]. In addition, 82 
dietary patterns rich in inorganic NO3
-
, such as the Dietary Approach to Stop Hypertension 83 
(DASH diet), have been associated with a reduction in resting systolic and diastolic BP of 84 
5.2mmHg and 2.2mmHg, respectively[12].  85 
 86 
Twenty-four hour ambulatory BP monitoring (24-hr ABPM) is a reference method for the 87 
diagnostic assessment of hypertension and monitoring of anti-hypertensive treatments[13; 88 
14]. This method provides information on circadian BP rhythm such as mean diurnal and 89 
nocturnal BP, BP variability, night dipping and morning surge[15]. Abnormal values of any 90 
of these indexes are independently associated with a greater haemodynamic load and CVD 91 
risk[16]. The effects of inorganic NO3
-
 supplementation on measures of 24-hr BP variability 92 
have not been investigated. We hypothesised that inorganic NO3
-
 supplementation may 93 
increase nitric oxide (NO) bioavailability[9], via an NO-synthase independent NO generation, 94 
and influence both mean values and variability of systolic BP. We also predicted that these 95 
effects were more significant on nocturnal BP, which may be explained by the diminution of 96 
the putative, confounding effects of physical activity and mental stress on BP regulation.  97 
 98 
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To address these hypotheses, we collated 24-hr ABPM data originally collected in four 99 
independent randomised clinical trials testing the effects of beetroot juice supplementation, as 100 
a rich source of inorganic NO3
-
, for a minimum of one week on 24-hr ABPM variability, 101 
diurnal and nocturnal BP, night dipping, morning surge and ambulatory arterial stiffness 102 
index (AASI) in older subjects (≥55 years). The individual data included in each trial were 103 
entered in a meta-analytical model to calculate the pooled effect size for each 24-ABPM 104 
systolic and diastolic outcome. Finally, we investigated whether the efficacy of inorganic 105 
NO3
-
 on 24-hr ABPM outcomes was modified by ageing, gender, obesity, high BP and 106 
magnitude of post-supplementation rise in nitrite (NO2
-
) concentrations. 107 
 108 
2. Methods 109 
2.1 Study Design: 110 
All trials were conducted in the UK and recruited older men and women aged 55 years and 111 
older. A description of the trial protocols has been previously reported for Trial-1[17] and 112 
Trial-3[18]. A description of the protocols of Trial-2 and Trial-4 is provided in the Online 113 
Supplementary Material. Briefly, two trials were conducted in Newcastle upon Tyne 114 
(Newcastle University, Trial-1, Trial-2) and two trials were conducted in Exeter (Exeter 115 
University, Trial-3, Trial-4). Both Newcastle-led trials had a two-arm, parallel study design. 116 
Trial-1 had a duration of three weeks and included blackcurrant juice as control (200 ml/day) 117 
and supplementation of 70 ml/day of concentrated beetroot juice (~4.5 mmol nitrate/day). 118 
Trial-2 had a duration of one week and included a negative control (diet only) and 119 
supplementation of 140 ml/day (~9.0 mmol nitrate/day) of concentrated beetroot juice. Both 120 
Exeter-led trials had a cross-over, double-blind, placebo controlled study design. Trials 3 and 121 
4 had both a duration of two weeks and included alternate, random supplementation of 250 122 
ml/day of NO3
-
-rich beetroot juice (7.5mmol nitrate/day active) or 250 ml/day of NO3
-
-123 
depleted beetroot juice (0.002mmol nitrate/day, placebo). All beetroot juice supplements 124 
were provided by the same company (James White Drinks Ltd., UK). 125 
 126 
2.2 Subjects: 127 
A total of 85 non-smoking men and women (M/F: 50/35), aged 55–76 years old with body 128 
mass index (BMI) between 20.2 and 39.5 kg/m
2
 were recruited at the Newcastle and Exeter 129 
research centres.Trial-1 was approved by the Newcastle University - Faculty of Medical 130 
Sciences Ethics Committee (Application No. 00628/2013). Trial-2 was approved by the 131 
North East - Northern & Yorkshire Research Ethics Committee (Study No. 12/NE/0134). 132 
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Trials 3 and 4 were both approved by the Devon and Torbay Research Ethics Committee 133 
(Study No. 09/H0202/43).Written informed consent was obtained from all participants prior 134 
to participation in each trial. 135 
 136 
2.3 Study Protocol 137 
Newcastle: A telephone screening interview was conducted to ensure eligibility of 138 
participants. Participants attended the research facilities at Newcastle University in fasting 139 
conditions. Anthropometric measurements (weight, height and waist circumference) were 140 
performed and body mass index (BMI) calculated. Participants were then randomized to one 141 
of two interventions (Trial 1: beetroot or blackcurrant juice; Trial 2: beetroot or diet only) and 142 
baseline measurements including resting BP, collection of saliva (Trial-1) and plasma (Trial-143 
2) samples, and completion of the International Physical Activity Questionnaire (IPAQ) for 144 
the assessment of physical activity. At the end of the visit participants were fitted with a 24-145 
hour AMBP monitor to continuously assess BP over the next 24-hour period. Saliva samples 146 
were transferred to a −20 °C freezer within 2 hours of collection. Fasting blood samples were 147 
collected in lithium heparin tubes and centrifuged within 30min from collection. Plasma 148 
samples were then immediately transferred to a −80 °C freezer. 149 
The intervention phase started immediately after the completion of the 24-hour BP 150 
monitoring period and lasted for 21 and 7 days for Trial-1 and Trial-2, respectively. During 151 
this phase, each participant was expected to comply with the assigned nutritional intervention 152 
and dietary plan to standardise NO3
-
 intake. At the end of the intervention, participants 153 
returned to the research unit to repeat the same set of measurements performed at baseline.  154 
Exeter: Subjects were recruited from the Exeter 10000 (EXTEND) bio-resource[18]. Eligible 155 
participants were randomized to begin, in either order, a 2-week period of supplementation 156 
with 250 ml of beetroot juice daily or 250 ml of NO3
-
-depleted beetroot juice, followed by a 157 
4-week washout period before entering the second arm of the study. Subjects were instructed 158 
to consume the juice along with their evening meal to minimize any potential glycaemic 159 
excursion, typically between 1800 and 2000 hours. Participants continued their usual 160 
antihypertensive medication and their usual hypoglycaemic medications including 161 
metformin. Hypoglycaemic agents were omitted on visits for which subjects were fasted. 162 
Twenty-four-hour blood pressure monitoring was performed from 0900 on day 13 of each 163 
supplementation arm. Fasting blood samples for NO3
-
 and NO2
-
 were collected into lithium 164 
heparin collection tubes. Samples were centrifuged immediately and plasma was immediately 165 
separated and flash-frozen in liquid nitrogen before transfer to a −80 °C freezer. 166 
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2.4 Nutritional Supplementation: 167 
Newcastle: Participants enrolled in Trial-1 and randomised to the intervention group were 168 
asked to every morning drink 70 ml of concentrated beetroot juice (Beet-It Sport Shot, James 169 
White company Ltd, Ipswich UK, 71 kcal). Each bottle (70 ml) provides approximately 300-170 
400 mg of inorganic NO3
-
. Participants randomised to the control group were asked to every 171 
morning drink 200 ml of blackcurrant juice (Capri-Sun Blackcurrant Juice, 100kcal), 2.7±0.1 172 
mg NO3
-
 per bottle. Participants enrolled in Trial-2 and randomised to the intervention group 173 
were asked to drink 70 ml of concentrated beetroot juice in the morning and 70 ml in the 174 
evening. Participants randomised to the control group were asked to follow the diet only. 175 
Participants in both trials were required to follow a diet to standardize NO3
-
 intake during the 176 
period of study. A description of the diet has been previously reported[17]. Participants were 177 
also asked not to change daily physical activities, to avoid the use of mouthwash during the 178 
study and to limit alcohol and caffeinated drink consumption during the study period. 179 
Exeter: Participants were given either 250 ml beetroot juice (active) or 250 ml NO3
-
-depleted 180 
beetroot juice (placebo) for two weeks. The untreated juice used in the active arm of the trial 181 
provided approximately 480 mg of NO3
-
 per day and the placebo juice provided 0.15 mg of 182 
NO3
-
 per day. Throughout the study patients were asked to maintain their normal diet apart 183 
from the juices given and not to change any other lifestyle factors. They were asked to 184 
continue their usual physical activity levels. Diet and activity levels were not monitored in 185 
the study. 186 
 187 
2.5 Resting Blood Pressure 188 
Newcastle: Resting BP was measured in triplicate using an automated BP monitor (Trial 1: 189 
Omron M2 Basic, Omron Healthcare, UK; Trial 2: CARESCAPE V100 monitor, GE 190 
Healthcare, UK) with the patient seated comfortably for 15 min prior to measurement and the 191 
arm supported at the level of the heart. The final value was calculated as the mean of the 192 
lowest two measurements. A large cuff was used for obese subjects. 193 
Exeter: Resting BP was measured using an automated BP monitor (Omron M6, Kyoto, 194 
Japan) with the patient seated comfortably for 15 min prior to measurement and the arm 195 
supported at the level of the heart. Five measurements were taken in total and the mean of the 196 
last three was recorded. A large cuff was used for obese subjects. 197 
 198 
2.6 24-hrABPM 199 
Newcastle: A validated device approved by the British Hypertension Society was used to 200 
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monitor 24-hr systolic and diastolic BP (Mobil-O-Graph NG, I.E.M. GmbH). All participants 201 
were  instructed  with  respect  to  the  use  and the  way  the  device  operates. During 202 
monitoring BP was measured every 30min at daytime (between 0700 and 2200) and every 203 
60min at night (between 2200 and 0700). Patients were advised to continue their normal 204 
activity during the monitoring period. All of the valid recordings were analysed to obtain 205 
average 24-hour systolic and diastolic BP. 206 
Exeter: Each participant was fitted with a TM-2430 ambulatory blood pressure monitor 207 
(A&D Medical, Draycott, Gloucestershire, UK) (validated by the British Hypertension 208 
Society). The device was programmed to record BP every 15min between the hours of 0700 209 
and 2200 and every 30min from 2200 to 0700. Participants were advised they could carry out 210 
their usual activities but to avoid strenuous exercise. All of the valid recordings were 211 
analysed to obtain average 24-hour systolic and diastolic BP. 212 
 213 
2.7 24-hr Blood Pressure Outcomes 214 
The same protocol was applied to the raw BP data to derive the ambulatory BP outcomes for 215 
both systolic and diastolic BP. 24-hr ABPM profiles were checked and systolic BP readings 216 
>250 or <70 mmHg, diastolic BP >150 or <40 mmHg were excluded. 24-hour mean BP is the 217 
average of the BP values recorded over 24-hours. Mean BP values were also calculated for 218 
diurnal (0715to 2145) and nocturnal (2200 to 0700). Weighted standard deviation (SD) for 219 
24-hour, diurnal and nocturnal BP values was calculated as a measure of BP variability. 220 
Night BP dipping was calculated as the difference between nocturnal and diurnal BP. 221 
Morning surge was calculated as the difference between post-awakening BP (0715 to 0900) 222 
and nocturnal BP. The ambulatory arterial stiffness index (ASSI) was calculated as 1 minus 223 
the regression slope of DBP on SBP from ABPM[19].  224 
 225 
2.8 Nitrate and Nitrite Concentrations 226 
Newcastle: A modified version of the method proposed by Tsikas et al[20] was used to 227 
determine NO3
-
 and NO2
-
 concentrations in saliva (Trial-1) and plasma (Trial-2) samples 228 
using gas chromatography mass spectrometry (GC-MS). The validation and protocol of the 229 
modified GC-MS method has been described elsewhere[21]. This method showed a good 230 
repeatability, as coefficients of variation for replicate analyses of samples were 7.8%, 8.6% 231 
and 12.0% in saliva, urine and plasma samples, respectively.  232 
Exeter: Before analysis, samples were deproteinized using a modification of the technique 233 
described by Higuchi and Motomizo[22]. Plasma NO3
-
 and NO2
-
 concentrations were 234 
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determined using a Sievers nitric oxide analyzer (Sievers NOA 280; Analytix Ltd, Durham, 235 
UK) using the methods described by Bateman et al.[23]. The between-batch coefficient of 236 
variation for NO3
-
 was 13% and for NO2
-
 was 8%. 237 
 238 
2.9 Statistical Analysis 239 
All statistical analyses were completed using SPSS for Windows (SPSS, version 17.0; SPSS 240 
Inc, Chicago, Ill, USA). Summary data are presented as mean (SD or 95%CI). P values<0.05 241 
(2-tailed) were considered as statistically significant. 242 
Newcastle: A general linear model was used to test differences in BP outcomes between the 243 
two nutritional interventions (beetroot, control). Analyses were adjusted for baseline values 244 
of the selected outcome. Post-intervention means and 95%CI are reported for each trial.  245 
Exeter: Paired t-test was used to compare differences in BP outcomes between the two 246 
nutritional interventions (beetroot, placebo). Post-intervention means and 95%CI are reported 247 
for each trial. 248 
Meta-analysis: A two-step meta-analysis of individual data was performed to pool together 249 
the summary statistics of each trial[24]. Meta-analysis was performed by using 250 
Comprehensive Meta-Analysis software (version 2, Biostat, Englewood, New Jersey, USA). 251 
The post-intervention least-squares means and SD values of each 24-hr ABPM outcome for 252 
both intervention and control groups were extracted and used in the analysis of parallel trials. 253 
The end of intervention mean differences and SD values of the differences between 254 
intervention and control were used for the analysis of cross-over trials. Data synthesis, 255 
including calculation of effect sizes with 95%CI, was accomplished by employing fixed or 256 
random-effect models. Random effects models were employed when a substantial 257 
heterogeneity between trials was observed (I
2
>50%)[25]. Heterogeneity was evaluated by the 258 
Cochran’s Q test and I2 calculated. Subgroup analyses were undertaken to investigate the 259 
variables which influenced the effects of beetroot juice supplementation on 24-hr ABPM 260 
outcomes. These factors included: age (<65y, ≥65y), gender (male, female), BMI (<30.0 261 
kg/m
2, ≥30.0 kg/m2), resting BP status (high, normal) and percent changes in saliva (Trial 1) 262 
and plasma (Trial 2, 3, 4) NO2
-
 concentrations after supplementation. Percent changes 263 
relative to baseline were calculated for salivary and plasma changes in NO2
-
 concentrations 264 
after beetroot supplementation. The median (50
th
 centile) of the distribution was calculated to 265 
compare the effects between subjects with lower (<50
th
 centile) vs higher (≥50th centile) 266 
changes in NO2
-
 concentrations on 24-hr ambulatory BP outcomes. Meta-regression analysis 267 
was performed to evaluate whether changes in NO2
-
 concentrations were associated with 268 
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changes in 24-hr ambulatory BP outcomes. High BP was defined as having a systolic BP 269 
≥140 mmHg or diastolic BP ≥90 mmHg. A mixed-effect model was used to evaluate within-270 
factor (pwithin) and between-factor (pbetween) significant differences in effect size for each 24-hr 271 
ABPM outcome.  272 
 273 
3. Results  274 
Participants’ Baseline Characteristics 275 
A total of 50 males and 35 females older participants (63.8±5.2 years) were included in the 276 
final analysis. Seventeen healthy normal weight participants (BMI: 25.6±2.5 kg/m
2
) were 277 
included in Trial-4; 21 and 20 overweight and obese participants were included in Trial-1 278 
(BMI: 30.1±4.2 kg/m
2
) and Trial-2 (BMI: 29.8±4.5 kg/m
2
), respectively. Trial-3 included 27 279 
obese type 2 diabetic participants (BMI: 30.7±3.1kg/m
2
).The average resting systolic and 280 
diastolic BP were 138.7±16.4 mmHg and 79.5±9.6 mmHg, respectively and 36 subjects had a 281 
high resting systolic (154.1±11.2 mmHg) and diastolic (85.7±8.3 mmHg) BP. Baseline 282 
characteristics of the two parallel trials were not significantly different between interventions. 283 
Table 1 shows the baseline characteristics of the subjects included in each trial. BP 284 
medications were prescribed only in 26 type 2 diabetic patients (Trial 3) whereas participants 285 
in the other three trials were free of anti-hypertensive medications. Additional baseline 286 
characteristics for each trial are reported in Table S1 of the Online Supplementary 287 
Material. 288 
 289 
3.1 Individual Trials 290 
Systolic BP: Overall, each trial showed no significant effect of beetroot juice 291 
supplementation on all 24-hr ambulatory BP outcomes. Only Trial-1 showed a significant 292 
increase in morning surge (11.0mmHg, 0.1, 22.9, p=0.04) which was not observed in the 293 
other trials (Table 2). 294 
Diastolic BP: Overall, trials showed no significant effect of beetroot juice supplementation on 295 
all 24-hr ambulatory BP outcomes. Only Trial-1 and Trial-3 showed a significant increase in 296 
morning surge (9.0mmHg, -1.7 16.3, p=0.02) and night dipping (2.6 mmHg, -0.3 4.8, 297 
p=0.02), respectively. However, these results were not confirmed in the other trials (Table 3). 298 
AASI: Beetroot juice supplementation was not associated with significant changes in AASI 299 
in each trial (Table S2, Online Supplementary Material). 300 
 301 
3.2 Main Meta-Analysis 302 
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Beetroot juice supplementation was not associated with significant changes in systolic and 303 
diastolic 24-hrABPM outcomes when results from the four trials were pooled together. Fixed 304 
models were applied to all BP outcomes because of the non-significant heterogeneity (I
2
 305 
range: 0 - 41%) with the exception of morning surge (systolic BP, I
2
=61%; diastolic BP, 306 
I
2
=74%) which employed a random model to derive the pooled estimates (Table 4). Beetroot 307 
juice supplementation was not associated with significant changes in AASI (Table S3, 308 
Online Supplementary Material). 309 
 310 
3.3 Sub-group Meta-Analysis 311 
Age: Beetroot juice supplementation determined a significant decrease in nocturnal systolic 312 
BP variability in subjects aged less than 65y (2.8 mmHg, -4.5 -1.0, pwithin=0.002) compared to 313 
the older group (≥65y; 1.0mmHg, -2.2 4.2, pwithin=0.54) and a significant difference between 314 
the two age groups was observed (pbetween=0.04). In addition, beetroot juice had a 315 
significantly lower effect on night dipping in older subjects (3.3mmHg, 0.2 6.4, pwithin=0.03) 316 
compared to younger subjects (-1.4mmHg, -4.2 1.4, pwithin=0.33; pbetween=0.02). No significant 317 
between-group differences were observed for diastolic BP (Table 5).  318 
Gender: We did not observe significant differences for all 24-hr ambulatory systolic BP 319 
outcomes between male and female subjects. A marginal effect was observed for nocturnal 320 
diastolic BP variability with lower variability observed in female compared to male subjects 321 
(pbetween=0.05) (Table 5).  322 
BMI: Body size had a marginal effect on both systolic and diastolic BP outcomes. Normal 323 
weight and overweight subjects appeared to have a significant lower nocturnal systolic BP 324 
variability (-1.9 mmHg, -3.6 -0.2, pwithin=0.03) compared to obese subjects (Table 5).   325 
Resting BP: Overall, we did not observe significant differences for all 24-hr ambulatory 326 
systolic BP outcomes between subjects with normal or raised BP. A marginal effect was 327 
observed for nocturnal systolic BP variability in subject with normal BP (-2.1 mmHg, -4.2 328 
0.08, pwithin=0.06) (Table 5). 329 
Δ%[NO2
-
]: The median (50
th
 centile) of the percent change in NO2
-
 concentrations after 330 
beetroot juice supplementation in the four trials was 30.9%. Subjects with greater changes in 331 
NO2
-
 concentrations (≥50th centile) showed a significant difference for nocturnal mean 332 
systolic BP (-3.4 mmHg -0.6 -2.4, pbetween=0.02), nocturnal systolic BP variability (-0.8 333 
mmHg, -1.5 -0.06, pwithin=0.03) and night dipping (-2.5 mmHg, -3.4 -1.9, pwithin=0.01) (Table 334 
5). Meta-regression showed a significant association between percent changes in NO2
-
 335 
concentrations with nocturnal mean systolic BP (β=-0.01±0.006 mmHg, p=0.04) (Figure S1, 336 
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Online Supplementary Material). The association was not significant with other 24-hr BP 337 
outcomes (data not showed). Percent changes in NO2
-
 concentrations were not associated 338 
with a significant effect on AASI (Table S4, Online Supplementary Material). 339 
4. Discussion  340 
This meta-analysis of individual participant data presents the most comprehensive evaluation 341 
to date on the effects of beetroot juice supplementation on 24-hr ABPM in older subjects. Our 342 
results showed that the main effect of inorganic NO3
-
 on 24-hr ABPM outcomes was not 343 
significant. However, sub-group analyses revealed ageing and post-supplementation changes 344 
in NO2
-
 concentrations as potential factors influencing the association between inorganic 345 
NO3
-
 and vascular responses. The latter highlights the clustering of the population into two 346 
distinct phenotypes, named as“reducers” and “non-reducers”, discriminated by their 347 
efficiency in reducing inorganic NO3
-
 into NO2
-
, which is closely correlated with the vascular 348 
response. The mechanisms underpinning these individual differences are still largely under-349 
investigated and they may involve the oral microbiota, gastric redox environment, oxygen 350 
tension and pH in the peripheral circulation or efficiency of enzymatic reductase activity (i.e., 351 
deoxy-haemoglobin, aldehyde dehydrogenase, xanthine oxido-reductase)[9; 26]. In addition, 352 
the ageing process may play a role in all these mechanisms. Ageing is associated with 353 
changes in oral microflora which may influence the efficiency of bacterial reductase activity 354 
in the conversion of NO3
-
 into NO2
-
[27]. In addition, gastric acid production declines with 355 
age[28]and this process may affect the formation of NO in the acid stomach from the acid-356 
mediated disproportionation of NO2
-
[29].  Hence, it is currently not known whether greater 357 
doses of inorganic NO3
- 
are required in older people to account for the decline in redox 358 
potential and augment NO bioavailability. Ageing may also be associated with diminished 359 
sensitivity of vascular smooth muscular cells (VSMCs) to the dilatory effects of NO, thus 360 
higher doses may be required[30]. This reduced sensitivity causes an impaired NO-dependent 361 
vasodilation as demonstrated by a reduced in vitro response of VSMCs to NO with 362 
ageing[31], which may contribute to explain the reduced vascular responses in older 363 
participants.  364 
The effects of beetroot juice supplementation mainly influence nocturnal systolic BP. A 365 
diminished nocturnal fall in BP is an independent risk factor for arterial stiffness and recent 366 
findings have identified mean nocturnal BP as a sensitive predictor of cardio- and 367 
cerebrovascular morbidity and mortality[32; 33]. Cardiovascular risk decreased by 17% for 368 
every 5 mmHg decrease in nocturnal systolic BP in both hypertensive and non-hypertensive 369 
populations even after adjusting for sex, age, diabetes, baseline BP and hypertension 370 
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medications[34]. These results may suggest a putative role played by either physical activity 371 
or emotional stress in confounding the effects of inorganic NO3
-
 on diurnal BP measured by 372 
24-hr ABPM. These two factors are known for modifying the reliability of the technique as 373 
well as cardiovascular responses and, therefore, potentially introducing a bias in the 374 
measurement of diurnal BP[35]. In addition, inorganic NO3
-
 plays a role in skeletal muscle 375 
energetics[36] and it may contribute to the non-significant effect of inorganic NO3
-
 on diurnal 376 
BP. A recent study has also suggested that skeletal muscle may serve as a nitrate reservoir, 377 
for direct formation of nitrite and NO, and for determining levels of nitrate in other 378 
organs[37]. We hypothesise that inorganic NO3
- 
supplemented during the more active diurnal 379 
hours may be utilised by the skeletal muscle and channelled towards metabolic functions, 380 
which may reduce its availability for vascular regulatory mechanisms. Rassaf et al.[38] have 381 
demonstrated that physical activity may unmask endothelial dysfunction and impaired 382 
cardiovascular function by enhancing a greater conversion of NO2
-
 into NO, by virtue of 383 
lower PO2 and pH in muscular tissue of subjects with major cardiovascular risk factors. The 384 
same research group also demonstrated that healthy older subjects failed to adequately 385 
increase circulating NO2
-
 after exercise[39]. The effects of inorganic nitrate on muscular 386 
metabolism and exercise energetics in older subjects and the partitioning of dietary nitrate 387 
towards metabolic and vascular functions are a novel area of research and future studies are 388 
needed to test these hypotheses.  389 
This is the first analysis that has collected individual data from the only four randomised 390 
clinical trials that, to date, have investigated the effects of inorganic NO3
-
 supplementation on 391 
24-hr ABPM. Three other trials have tested the effects of beetroot-based interventions on 24-392 
hr ABPM. Two trials have not been considered for inclusion as they have evaluated the acute 393 
effects (i.e., one day) of a single dose of beetroot juice on 24-hr ABPM outcomes[40; 41]. 394 
The third trial was conducted in patients with hypertension aged 18 to 85 years. The trial 395 
reported a significant effect of beetroot juice on 24-hr, daily and nocturnal systolic BP 396 
whereas the effect on BP variability has not been reported[42]. An additional strength of our 397 
analysis is represented by the sample size which is the largest available dataset testing the 398 
effects of inorganic NO3
-
 supplementation on 24-hr ABPM outcomes. A posteriori sample 399 
size calculations showed a power of 81% to detect differences in BP of ±3.0mmHg (SD 400 
7.5mmHg) between control and intervention groups. A limitation of the analysis is the 401 
difference in study design between trials. However, the heterogeneity of the pooled estimates 402 
ranged from moderate to low for all 24-hr ABPM outcomes, which denoted an overall 403 
between-study agreement of the effects of beetroot juice on 24-hr ABPM outcomes. Morning 404 
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surge was the only BP outcome with high heterogeneity and therefore a random model was 405 
applied to derive the pooled effect size. The trials showed differences in the collection of 406 
biological samples (saliva, blood) to test for changes in NO3
- 
and NO2
- 
during 407 
supplementation; however, the exclusion of the saliva samples from the analysis did not 408 
modify the association between nocturnal BP outcomes and changes in NO2
- 
concentrations. 409 
Subjects with type 2 diabetes (Trial 3) were on anti-hypertensive medications during the 410 
beetroot juice supplementation, which may have also influenced the study outcomes. 411 
However, the exclusion of Trial 3 from the meta-analysis did not modify the pooled results as 412 
we still observed a significant influence of ageing and changes in NO2
-
 on nocturnal mean, 413 
variability and dipping of systolic BP. An additional limitation of the analysis was the 414 
inability to test the biological mechanisms that may have explained the significant effects of 415 
beetroot juice supplementation on nocturnal systolic BP as well as the putative role of ageing 416 
in modifying the effects of dietary NO3
- 
on vascular function. Biological factors may include 417 
NO3
- 
  partitioning between vascular and metabolic effects during diurnal activities and the 418 
role of ageing in the influencing the reducing steps converting NO3
- 
 into NO2
- 
 and NO 419 
and/or biological responsiveness of target cells to NO activity. This information was however 420 
not available in the four trials included in the meta-analyses. We therefore advocate for a 421 
careful interpretation of our results until these mechanisms will be tested in future studies.  422 
 423 
5. Conclusions 424 
Ageing and changes in NO2
-
 concentrations modified the effects of beetroot juice, as a rich 425 
source of inorganic NO3
-
, on nocturnal systolic BP variability. The vascular responsiveness to 426 
inorganic NO3
-
 may be modified by mechanisms of vascular ageing and efficiency of the 427 
reductase activity converting inorganic NO3
-
 into NO2
-
. If confirmed in future studies, these 428 
findings may open novel opportunities to improve personalised nutrition for the management 429 
of hypertension. 430 
 431 
 432 
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 579 
Table 1: Descriptive statistics of the four trials included in the analysis.  
 Trial 1PL Trial 2PL Trial 3CO Trial 4CO 
 Beetroot Control p  Beetroot Control p All p All p 
N 10 11  10 10  27 - 17 - 
M/F 7/3 5/6 0.38 4/6 5/5 0.87 18/9 -  - 
Age (years) 62.7±4.9 61.4±4.3 0.54 64.9±6.1 61.4±3.4 0.13 67.2±4.9 - 60.5±3.6 - 
Height (m) 1.74±0.11 1.69±0.11 0.28 1.69±0.08 1.69±0.11 0.86 1.68±0.08 - 1.74±0.10 - 
Weight (kg) 92.5±15.4 84.2±14.6 0.21 84.3±16.4 86.5±13.4 0.76 87.1±11.5 - 78.7±12.3 - 
BMI (kg/m2) 30.5±4.4 29.4±4.1 0.55 29.7±4.9 30.0±4.2 0.89 30.7±3.1 - 25.6±2.5 - 
WC (cm) 103.8±12.8 100.7±10.1 0.55 103.0±11.9 97.8±24.5 0.77 106.1±8.0 - 93.3±10.5 - 
Resting SBP 135.1±14.8 131.1±14.8 0.54 146.9±19.8 143.8±20.3 0.73 142.8±13.9 - 131.6±16.0 - 
Resting DBP 77.4±9.5 76.1±10.9 0.78 79.3±8.5 77.8±12.7 0.66 81.1±9.1 - 80.0±9.57 - 
Data are presented as mean±SD; N= number of subjects; M/F=male/female; BMI=body mass index; WC= waist circumference;  580 
SBP= systolic blood pressure; DBP= diastolic blood pressure; PL= parallel study design; CO= cross-over study design.  581 
T test for independent samples was used to compare the two groups in parallel trials.(Trial 1,2: Newcastle) and (Trial 3,4: Exeter) 582 
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Table 2: Effects of beetroot juice supplementation on systolic blood pressure outcomes measured by 24-hr ambulatory blood pressure monitoring. Results are presented individually for each trial included in the meta-analysis.  
 Trial 1PL Trial 2PL Trial 3CO Trial 4CO 
 Beetroot Control Δ p  Beetroot Control Δ P Beetroot Control Δ p  Beetroot Control Δ p  
24-hour Mean  126.3  
(119.9, 132.7) 
127.9  
(121.8, 134.0) 
-1.5 
(-10.4, 7.3) 
0.72 127.6  
(123.9, 131.4) 
124.7  
(120.9, 128.4) 
2.9  
(-2.4, 8.3) 
0.26 135.1 
(132.0, 135.8) 
134.5 
(131.2, 137.8) 
0.6  
(-2.7, 3.9) 
0.72 131.0 
(124.3, 137.8) 
129.8 
(124.5, 135.2) 
1.1  
(-2.1, 4.5) 
0.46 
24-hour SD 14.7 
(11.4, 17.9) 
15.4 
(12.3, 18.5) 
-0.7 
(-5.2, 3.8) 
0.75 16.5 
(13.3, 19.7) 
14.6 
(11.4, 17.8) 
1.9 
(-3.8, 5.2) 
0.38 20.9 
(19.7, 22.1) 
21.2 
(19.6, 22.8) 
-0.3 
(-1.7, 1.2) 
0.68 18.8 
(16.6, 21.0) 
19.3 
(16.8, 21.8) 
-0.5 
(-2.6, 1.6) 
0.64 
Diurnal Mean 130.5 
(123.6, 137.5) 
131.2 
(124.5, 137.9) 
-0.7 
(-10.4, 9.0) 
0.88 132.2 
(127.0, 137.3) 
128.3 
(123.2, 133.5) 
3.8 
(-3.5, 11.1) 
0.29 138.8 
(135.0, 142.6) 
138.9 
(135.0, 142.9) 
-0.2 
(-3.8, 3.5) 
0.93 135.5 
(129.2, 141.7) 
134.3 
(129.1, 139.4) 
1.2 
(-2.0, 4.3) 
0.45 
Diurnal SD 13.1 
(9.4, 16.9) 
14.8 
(11.2, 18.4) 
-1.6 
(-6.9, 3.6) 
0.52 14.6 
(11.5, 17.6) 
13.4 
(10.4, 16.4) 
1.2 
(-3.2, 5.5) 
0.58 19.7 
(18.3, 21.1) 
19.8 
(18.2, 21.4) 
-0.1 
(-1.5, 1.4) 
0.88 17.6 
(15.2, 20.3) 
17.9 
(15.1, 20.6) 
-0.3 
(3.0, 2.4) 
0.82 
Nocturnal Mean 115.6 
(109.0, 122.3) 
121.2 
(114.8, 127.6) 
-5.5 
(-14.8, 3.6) 
0.22 111.1 
(106.5, 115.7) 
115.4 
(110.8, 120.0) 
-4.3 
(-10.8, 2.1) 
0.17 123.3 
(120.2, 126.4) 
121.2 
(116.9, 125.5) 
2.1 
(-1.6, 5.8) 
0.26 117.4 
(107.9, 126.9) 
116.1 
(109.2, 123.0) 
1.3 
(-3.8, 6.4) 
0.59 
Nocturnal SD 11.1 
(8.3, 13.9) 
13.4 
(10.7, 16.1) 
-2.3 
(-6.2, 1.5) 
0.22 11.5 
(8.6, 14.3) 
11.8 
(9.0, 14.7) 
-0.3 
(-4.3, 3.6) 
0.85 16.9 
(14.8, 19.1) 
16.6 
(14.4, 18.7) 
0.3 
(-2.0, 2.8) 
0.75 13.0 
(11.0, 15.1) 
15.4 
(12.2, 18.7) 
-2.4 
(-6.0, 1.2) 
0.17 
Dipping -14.9 
(-20.0, -9.8) 
-9.9 
(-14.7, -5.1) 
-4.9 
(-12.0, 2.1) 
0.15 -18.7 
(-24.8, -12.7) 
-15.1 
(-21.1, -9.0) 
-3.6 
(-12.2, 5.0) 
0.39 -15.4 
(-20.1, -10.8) 
-17.7 
(-22.9, -12.5) 
2.3 
(-1.8, 6.3) 
0.26 -18.0 
(-23.4, -12.6) 
-18.1 
(-22.2, -14.1) 
0.1 
(-3.9, 4.2) 
0.94 
Morning Surge 15.5 
(7.1, 23.8) 
4.0 
(-3.8, 12.0) 
11.0 
(0.1, 22.9) 
0.04 17.1 
(8.4, 25.7) 
12.0 
(3.4, 20.0) 
5.0 
(-7.5, 17.6) 
0.41 16.2 
(11.6, 20.9) 
20.8 
(15.9, 25.8) 
-4.5 
(-10.7, 1.6) 
0.58 14.2 
(7.7, 20.8) 
12.4 
(7.6, 17.3) 
1.8 
(-5.1, 8.7) 
0.14 
Data are presented as mean (95%CI). SD= standard deviation. PL= parallel study design; CO= cross-over study design; Δ= difference between beetroot and control group. Significant results are highlighted in bold. (Trial 1,2: Newcastle) and (Trial 3,4: Exeter)
Page 20 of 24
 21 
Table 3: Effects of beetroot juice supplementation on diastolic blood pressure outcomes measured by 24-hr ambulatory blood pressure monitoring. Results are presented individually for each trial included in the meta-analysis.  
 Trial 1PL Trial 2PL Trial 3CO Trial 4CO 
 Beetroot Blackcurrant Δ p  Beetroot Control Δ p Beetroot Control Δ p  Beetroot Control Δ p  
24-hour Mean  79.4 
(74.9, 83.9) 
80.1 
(75.8, 84.4) 
-0.7 
(-6.9, 5.5) 
0.81 78.2 
(76.1, 80.4) 
76.6 
(74.4, 78.8) 
1.6 
(-1.4, 4.7) 
0.28 75.1 
(73.0, 77.2) 
76.4 
(74.2, 78.6) 
-1.2 
(-3.1, 0.6) 
0.17 79.9 
(76.3.3, 83.5) 
79.5 
(76.1, 82.9) 
0.4 
(-2.1, 2.9) 
0.74 
24-hour SD 11.8 
(9.9, 13.8) 
11.0 
(9.2, 12.9) 
0.8 
(-1.8, 3.5) 
0.53 11.4 
(9.7, 13.1) 
10.9 
(9.1, 12.6) 
0.5 
(-1.8, 2.9) 
0.63 15.7 
(14.1, 17.2) 
16.5 
(14.7, 18.2) 
-0.8 
(-2.8, 1.2) 
0.40 15.1 
(12.9, 17.3) 
14.3 
(12.3, 16.3) 
0.8 
(-1.4, 2.9) 
0.46 
Diurnal Mean 82.9 
(77.9, 88.0) 
82.8 
(78.1, 87.6) 
-0.1 
(-6.0, 7.0) 
0.97 81.8 
(78.9, 84.7) 
79.6 
(76.7, 82.5) 
2.1 
(-2.0, 6.3) 
0.29 77.2 
(74.8, 79.6) 
79.3 
(76.7, 81.9) 
-2.1 
(-4.2, 0.1) 
0.06 83.0 
(79.7, 86.3) 
82.6 
(79.2, 85.9) 
0.4 
(-2.6, 3.5) 
0.76 
Diurnal SD 10.5 
(8.7, 12.2) 
9.4 
(7.8, 11.0) 
1.1 
(-1.3, 3.4) 
0.37 9.1 
(7.6, 10.5) 
9.1 
(7.7, 10.6) 
-0.08 
(-2.1, 1.9) 
0.93 15.7 
(14.0, 17.4) 
16.4 
(14.5, 18.4) 
-0.7 
(-3.0, 1.5) 
0.50 14.7 
(11.9, 17.4) 
13.8 
(11.4, 16.0) 
0.9 
(-1.6, 3.5) 
0.45 
Nocturnal Mean 70.5 
(65.6, 75.4) 
74.1 
(69.5, 78.8) 
-3.6 
(-10.3, 3.1) 
0.27 66.0 
(61.7, 70.2) 
68.5 
(64.3, 72.7) 
-2.5 
(-8.5, 3.4) 
0.38 68.3 
(66.0, 70.3) 
67.8 
(65.1, 70.5) 
0.5 
(-1.1, 2.1) 
0.51 70.4 
(65.0, 75.8) 
69.9 
(65.4, 74.5) 
0.5 
(-2.2, 3.1) 
0.71 
Nocturnal SD 9.5 
(7.0, 12.0) 
10.2 
(7.8, 12.5) 
-0.7 
(-4.1, 2.7) 
0.67 9.1 
(6.4, 11.7) 
10.5 
(7.9, 13.1) 
-1.4 
(-5.1, 2.3) 
0.43 11.9 
(10.4, 13.5) 
11.6 
(9.7, 13.4) 
0.3 
(-1.9, 2.7) 
0.74 10.0 
(8.5, 11.6) 
10.1 
(8.1, 12.1) 
-0.1 
(-2.4, 2.2) 
0.93 
Dipping -11.9 
(-16.4, -7.4) 
-9.1 
(-13.4, -4.8) 
-2.8 
(-9.0, 3.5) 
0.36 -14.4 
(-18.3, -10.5) 
-12.5 
(-16.4, -8.6) 
-1.9 
(-7.5, 3.6) 
0.48 -8.8 
(-11.6, -6.0) 
-11.4 
(-14.6, -8.2) 
2.6 
(-0.3, 4.8) 
0.02 -12.5 
(-16.1, -8.9) 
-12.6 
(-15.8, -9.3) 
0.1 
(-3.1, 3.2) 
0.97 
Morning Surge 14.6 
(9.6, 19.7) 
5.6 
(0.9, 10.4) 
9.0 
(-1.7, 16.3) 
0.02 12.2 
(7.3, 17.2) 
8.5 
(3.6, 13.5) 
3.7 
(-3.4, 10.8) 
0.29 10.0 
(6.3, 13.0) 
14.9 
(10.6, 19.1) 
-4.8 
(-9.9, 0.2) 
0.06 12.5 
(6.9, 18.0) 
12.7 
(9.3, 16.1) 
-0.2 
(-5.3, 4.8) 
0.92 
Data are presented as mean (95%CI). SD= standard deviation. PL= parallel study design; CO= cross-over study design; Δ= difference between beetroot and control group. Significant results are highlighted in bold. (Trial 1,2: Newcastle) and 
(Trial 3,4: Exeter) 
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Table 4: Meta-analysis of pooled data (N=85) for each blood pressure (BP) outcome obtained from the analysis of 24-hr ambulatory BP monitoring.  
 Systolic BP (mmHg) Diastolic BP (mmHg) 
 Effect Size 95%CI P Effect Size 95%CI P 
24-hour Mean  1.0 -0.9, 3.0 0.28 0.2 -1.4, 1.0 0.76 
24-hour SD 0.2 -0.8, 1.3 0.65 0.2 -0.8, 1.3 0.65 
Diurnal Mean 0.08 -0.1, 0.3 0.44 -0.6 -2.0, 0.8 0.41 
Diurnal SD -0.1 -1.2, 1.0 0.84 0.3 0.7, 1.3 0.58 
Nocturnal Mean 0.1 -2.3, 2.5 0.91 0.2 -1.0, 1.4 0.80 
Nocturnal SD -0.8 -2.3, 0.7 0.30 -0.2 -1.4, 1.0 0.72 
Dipping 0.1 -2.5, 2.2 0.90 1.0 -0.6, 2.5 0.23 
Morning Surge
R
 2.3 -4.0, 8.7 0.47 1.6 -4.0, 7.2 0.57 
SD= standard deviation; 95%CI= 95% Confidence Intervals. Fixed-effect models were applied to derive pooled estimates for BP outcomes expect for Morning  
Surge (R) which was derived using a random-effect model (see methods section for more details). 
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Table 5: Sub-group analysis to evaluate the effects of age, gender, body mass index (BMI), blood pressure (BP) and percent 
changes in nitrite concentrations (Δ[NO2]) on the pooled effect size for systolic and diastolic BP outcomes 
   Systolic BP (mmHg) Diastolic BP (mmHg) 
  N Effect Size 95%CI P Effect Size 95%CI P 
24-hour Mean Age <65y 
Age ≥65y 
46 
39 
0.7 
0.7 
-3.0, 4.4 
-3.6, 5.0 
0.99 
1.3 
-0.2 
-0.3, 3.0 
-2.5, 2.0 
0.28 
Male 
Female 
50 
35 
0.7 
0.5 
-1.8, 3.3 
-2.4, 3.5 
0.92 
0.6 
-0.01 
-1.9, 3.2 
-1.3, 1.3 
0.66 
BMI<30kg/m
2 
BMI≥30kg/m2 
53 
32 
0.2 
0.09 
-2.1, 2.5 
-3.1, 3.3 
0.95 
0.1 
-0.2 
-1.5, 1.7 
-2.2, 1.8 
0.80 
Raised Resting BP  
Normal Resting BP 
36 
49 
1.3 
1.0 
-2.3, 5.0 
-1.1, 3.1 
0.88 
0.1 
0.7 
-1.5, 1.8 
-1.3, 2.8 
0.66 
Δ[NO2]<50
th
 Centile 
Δ[NO2]≥50
th
 Centile 
40 
45 
2.4 
1.1 
-0.7, 5.6 
-2.3, 4.6 
0.58 
1.3 
0.1 
-0.7, 3.4 
-2.7, 2.8 
0.47 
24-hour SD Age <65y 
Age ≥65y 
46 
39 
-0.05 
0.2 
-1.5, 1.4 
-0.7, 1.1 
0.78 
0.1 
0.4 
-1.2, 1.4 
-1.6, 2.4 
0.79 
Male 
Female 
50 
35 
-0.5 
-0.3 
-1.9, 0.9 
-1.8, 1.1 
0.86 
0.4 
0.6 
-1.4, 2.1 
-0.5, 1.8 
0.78 
BMI<30kg/m
2 
BMI≥30kg/m2 
53 
32 
-0.5 
0.4 
-1.7, 0.7 
-1.4, 2.2 
0.43 
-0.2 
0.4 
-1,2, 0.9 
-1.7, 2.5 
0.63 
Raised Resting BP  
Normal Resting BP 
36 
49 
-0.1 
-0.3 
-2.6, 2.4 
-1.6, 1.0 
0.90 
1.1 
0.6 
-1.1, 3.4 
-0.7, 1.9 
0.67 
Δ[NO2]<50
th
 Centile 
Δ[NO2]≥50
th
 Centile 
40 
45 
0.1 
-0.4 
-1.6, 1.8 
-1.6, 0.8 
0.63 
0.9 
-0.2 
-0.7, 2.5 
-2.0, 1.6 
0.39 
Diurnal Mean Age <65y 
Age ≥65y 
46 
39 
1.9 
-1.2 
-0.5, 4.4 
-4.8, 2.4 
0.16 
0.8 
0.6 
-1.3, 3.0 
-4.1, 5.4 
0.92 
Male 
Female 
50 
35 
-0.2 
-0.3 
-2.4, 2.0 
-3.7, 3.0 
0.93 
-0.03 
0.1 
-0.3, 0.2 
-0.4, 0.7 
0.57 
BMI<30kg/m
2 
BMI≥30kg/m2 
53 
32 
1.0 
-0.5 
-2.3, 4.5 
-4.3, 3.1 
0.52 
0.5 
-0.5 
-2.9, 3.9 
-3.5, 2.3 
0.64 
Raised Resting BP  
Normal Resting BP 
36 
49 
0.7 
0.5 
-4.7, 6.2 
-1.7, 2.6 
0.92 
-0.06 
0.1 
-2.3, 2.2 
-2.5, 2.3 
0.96 
Δ[NO2]<50
th
 Centile 
Δ[NO2]≥50
th
 Centile 
40 
45 
3.0 
3.7 
-0.1, 6.2 
-4.9, 12.3 
0.89 
1.5 
-0.1 
-1.0, 4.2 
-3.2, 3.0 
0.42 
Diurnal SD Age <65y 
Age ≥65y 
46 
39 
0.08 
0.24 
-0.3, 0.4 
-0.5, 1.0 
0.72 
0.6 
-0.2 
-1.8, 2.9 
-1.6, 1.3 
0.60 
Male 
Female 
50 
35 
0.3 
-0.5 
-1.7, 2.2 
-1.8, 0.8 
0.51 
0.1 
0.6 
-0.7, 1.1 
-1.1, 2.4 
0.62 
BMI<30kg/m
2 
BMI≥30kg/m2 
53 
32 
0.1 
0.1 
-1.3, 1.1 
-1.8, 2.1 
0.83 
0.2 
0.4 
-0.6, 0.9 
-1.7, 2.5 
0.85 
Raised Resting BP  
Normal Resting BP 
36 
49 
-0.7 
0.2 
-3.9, 2.4 
-1.1, 1.5 
0.60 
0.5 
0.2 
-1.1, 2.3 
-0.8, 1.2 
0.73 
Δ[NO2]<50
th
 Centile 
Δ[NO2]≥50
th
 Centile 
40 
45 
-0.1 
-0.4 
-2.1, 1.9 
-1.7, 0.8 
0.81 
0.9 
-0.6 
-0.6, 2.4 
-2.8, 1.6 
0.28 
Nocturnal Mean Age <65y 
Age ≥65y 
46 
39 
-1.9 
0.4 
-3.4, -0.4 
-5.6, 3.5 
0.44 
0.3 
1.0 
-1.6, 2.4 
-1.8, 3.8 
0.70 
Male 
Female 
50 
35 
-3.1 
-1.3 
-6.4, 0.06 
-4.5, 1.9 
0.42 
-0.2 
-0.05 
-2.3, 1.9 
-2.1, 2.0 
0.92 
BMI<30kg/m
2 
BMI≥30kg/m2 
53 
32 
-0.6 
-3.3 
-3.8, 2.5 
-13.7, 7.0 
0.63 
0.4 
-4.0 
-1.0, 1.9 
-14.0, 6.0 
0.39 
Raised Resting BP  
Normal Resting BP 
36 
49 
-2.1 
1.1 
-8.5, 4.1 
-1.7, 4.0 
0.36 
-0.2 
0.4 
-2.7, 2.2 
-1.2, 2.0 
0.68 
Δ[NO2]<50
th
 Centile 
Δ[NO2]≥50
th
 Centile 
40 
45 
1.4 
-3.4 
-1.8, 4.7 
-0.6, -2.4 
0.02 
0.4 
-0.7 
-2.0, 2.8 
-1.9, 0.6 
0.44 
Nocturnal SD Age <65y 
Age ≥65y 
46 
39 
-2.8 
1.0 
-4.5, -1.0 
-2.2, 4.2 
0.04 
-2.3 
0.6 
-6.8, 2.1 
-4.9, 6.1 
0.41 
Male 
Female 
50 
35 
-0.8 
2.1 
-2.3, 0.7 
-0.4, 4.7 
0.04 
1.0 
-1.8 
-0.3, 2.2 
-4.2, 0.6 
0.05 
BMI<30kg/m
2 
BMI≥30kg/m2 
53 
32 
-1.9 
0.7 
-3.6, -0.2 
-1.9, 3.2 
0.09 
-0.2 
0.1 
-1.4, 1.0 
-2.4, 2.6 
0.82 
Raised Resting BP  
Normal Resting BP 
36 
49 
0.7 
-2.2 
-1.1, 2.4 
-4.2, -0.1 
0.04 
0.6 
-0.8 
-0.9, 2.1 
-2.5, 0.9 
0.23 
Δ[NO2]<50
th
 Centile 40 -0.6 -1.8, 0.5 0.86 -0.6 -2.5, 1.2 0.56 
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Δ[NO2]≥50
th
 Centile 45 -0.8 -1.5, -0.06 0.1 -1.6, 1.9 
Dipping Age <65y 
Age ≥65y 
46 
39 
-1.4 
3.3 
-4.2, 1.4 
0.2, 6.4 
0.02 
-0.3 
2.6 
-2.6, 1.9 
0.01, 5.1 
0.09 
Male 
Female 
50 
35 
0.03 
1.2 
-2.9, 2.9 
-3.0, 5.6 
0.64 
0.3 
0.4 
-2.6, 3,2 
-2.4, 3.2 
0.97 
BMI<30kg/m
2 
BMI≥30kg/m2 
53 
32 
0.4 
-4.4 
-2.4, 3.3 
-13.4, 4.5 
0.31 
0.9 
-2.4 
-1.8, 3.6 
-11.9, 6.9 
0.49 
Raised Resting BP  
Normal Resting BP 
36 
49 
-3.3 
0.4 
-9.6, 3.9 
-2.1, 2.9 
0.28 
-0.2 
0.9 
-3.9, 3.4 
-1.0, 2.9 
0.56 
Δ[NO2]<50
th
 Centile 
Δ[NO2]≥50
th
 Centile 
40 
45 
-0.5 
-2.5 
-2.6, 1.7 
-3.4, -1.9 
0.15 
-0.5 
-0.1 
-3.6, 2.6 
-3.4, 3.3 
0.85 
Morning Surge Age <65y 
Age ≥65y 
46 
39 
3.6 
-0.7 
-1.1, 8.5 
-13.2, 11.8 
0.52 
2.0 
-2.9 
-1.3, 5.3 
-9.6, 3.7 
0.19 
Male 
Female 
50 
35 
1.5 
1.8 
-4.2, 7.3 
-6.4, 10.1 
0.95 
0.1 
4.0 
-5.2, 5.6 
-2.6, 10.7 
0.38 
BMI<30kg/m
2 
BMI≥30kg/m2 
53 
32 
2.1 
3.5 
-2.5, 6.8 
-13.6, 20.8 
0.87 
0.4 
3.8 
-3.4, 4.2 
-7.3, 15.1 
0.56 
Raised Resting BP  
Normal Resting BP 
36 
49 
3.0 
0.8 
-3.9, 10.0 
-8.0, 9.5 
0.69 
3.6 
0.1 
-4.0, 11.4 
-5.4, 5.7 
0.47 
Δ[NO2]<50
th
 Centile 
Δ[NO2]≥50
th
 Centile 
40 
45 
-1.4 
7.0 
-6.1, 3.2 
-3.8, 18.0 
0.15 
-0.1 
1.9 
-4.1, 3.9 
-3.8, 7.8 
0.56 
SD= standard deviation. 95%CI= 95% Confidence Intervals. Significant results are highlighted in bold. Δ[NO2]<50
th Centile corresponds to the 
median of the distribution for percent changes in nitrite concentrations in plasma (Trial 1, Trial 3 and Trial 4) and saliva (Trial 2).  
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